A July 14, 2026 investigation by The Sick Times put a spotlight on something Long COVID patients have known for a while: peptides are being marketed hard for post-viral recovery, and the science is running well behind the marketing. The piece names BPC-157, MOTS-c, KPV, TB-500, and microdosed GLP-1s as compounds people are buying and injecting in the hope of clearing brain fog, fatigue, and inflammation.
Here's the honest state of play. Two GLP-1 drugs — semaglutide and tirzepatide — are in actual Long COVID clinical trials right now. The research peptides that dominate the online conversation are not; they're being used off-label or as research chemicals with no controlled Long COVID data behind them. This article separates what's being formally studied from what's being sold, and points you to sourcing and COA data for the compounds if you're already researching them.
Research-context information only. Compounds discussed below are research peptides and supplements; some are investigational drugs not approved by the FDA. Protocols, doses, and reactions reported come from published research and self-reported community sources. Possession or use of investigational drugs outside an authorized clinical trial may be illegal in your jurisdiction. This article reports what has been documented, not what should be done. Consult a licensed physician for personal medical decisions.
What's actually in trials
The two most credible Long COVID peptide programs are both GLP-1 receptor agonists, and neither has read out yet.
Semaglutide is being tested through the NIH's RECOVER-TLC initiative, with enrollment expected to begin in summer 2026 (The Sick Times, January 2026). The working hypothesis is that GLP-1 signaling dampens the chronic inflammation implicated in post-viral illness.
Tirzepatide is being studied in a separate, fully remote trial at Scripps Research, which recruited roughly 1,000 participants in under two months and expects data in late 2026 or early 2027. Because tirzepatide adds GIP agonism to the GLP-1 mechanism and semaglutide does not, comparing the two trials may show whether the GLP-1 component alone is doing the work.
Larazotide, an oral synthetic peptide originally developed for celiac disease, is in a Massachusetts General Hospital Long COVID trial. Its rationale is gut-barrier repair — the idea that viral antigen lingering in the gut drives symptoms. The Long COVID arm is ongoing with no results yet, but a related pediatric trial found larazotide safe and effective in children with post-COVID multisystem inflammatory syndrome (MIS-C), with faster viral spike-antigen clearance (PMID 40737433). That result is what pushed researchers toward the adult Long COVID test.
The research peptides getting the most social-media attention — BPC-157, TB-500, KPV, MOTS-c — have no Long COVID trials. Cardiologist Eric Topol, quoted by The Sick Times, put it bluntly: for most of these peptide claims "there are no data regarding safety and efficacy." A survey of 120 Long COVID patients trying peptides found 53% reported improvement and 28% reported worsening — self-reported, uncontrolled, and impossible to separate from the natural waxing and waning of the illness.
What this means if you're researching these compounds
If you're weighing peptides for post-viral recovery, the evidence hierarchy is clear: the GLP-1 trials are the only serious data pipeline, and they haven't reported. Everything else is anecdote. That doesn't tell you what to do — it tells you how thin the ground is.
For the compounds themselves, sourcing is the practical question people actually search for, because BPC-157 and MOTS-c compounding was restricted by the FDA and they now move almost entirely through the research-chemical market. If you're going to research them, third-party certificates of analysis (COAs) and per-milligram price are the two things that matter most. Our vendor pages track both. None of the four research peptides below have documented Long COVID trial data — the links track sourcing quality (COAs, pricing), not evidence of benefit for this condition:
- BPC-157 vendors and COAs — the most-cited research peptide in the article, sold for gut and connective-tissue research.
- MOTS-c vendors and COAs — a mitochondrial-derived peptide studied for metabolic and energy pathways.
- KPV vendors and TB-500 vendors — the two other research peptides named in the reporting.
- Semaglutide and tirzepatide — the two GLP-1s actually in Long COVID trials.
Because these are injectables, you'll also need bacteriostatic water to reconstitute lyophilized peptide powder. See current vendor discounts across the board on our deals page.
